Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis.

Small interfering RNA (siRNA) holds promise for treating rheumatoid arthritis by inhibiting major cytokines such as tumor necrosis factor-α (TNF-α). We developed original cationic amphiphilic phosphorus dendrons to produce dendriplexes associated with TNF-α siRNA. The dendrons were made of 10 pyrrolidinium end groups and a C17 aliphatic chain. The dendriplexes demonstrated the ability to protect siRNA from nuclease degradation and to promote macrophage uptake. Moreover, they led to potent inhibition of TNF-α expression in the lipopolysaccharide-activated mouse macrophage cell line RAW264.7 in vitro model. A significant anti-inflammatory effect in the murine collagen-induced arthritis model was observed through arthritis scoring and histological observations. These results open up essential perspectives in using this original amphiphilic dendron to reduce the disease burden and improve outcomes in chronic inflammatory diseases.

[1]  Xiaoxuan Liu,et al.  Amphiphilic Dendrimer Vectors for RNA Delivery: State-of-the-Art and Future Perspective , 2022, Accounts of materials research.

[2]  Á. González-Fernández,et al.  Improving dexamethasone drug loading and efficacy in treating arthritis through a lipophilic prodrug entrapped into PLGA-PEG nanoparticles , 2022, Drug delivery and translational research.

[3]  Jie Zhou,et al.  Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis , 2021, Frontiers in Pharmacology.

[4]  E. Fattal,et al.  Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases. , 2021, Advanced drug delivery reviews.

[5]  Hongtao Zhang,et al.  Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future , 2020, Genes & diseases.

[6]  A. Bohr,et al.  Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-α siRNA with PAMAM dendrimers in a murine model , 2020, European Journal of Pharmaceutics and Biopharmaceutics.

[7]  Bo Hu,et al.  Therapeutic siRNA: state of the art , 2020, Signal Transduction and Targeted Therapy.

[8]  E. Fattal,et al.  Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis. , 2020, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[9]  N. Guiblin,et al.  Nanoscale Lipophilic Prodrugs of Dexamethasone with Enhanced Pharmacokinetics. , 2019, Molecular pharmaceutics.

[10]  M. Espéli,et al.  Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Sabrina Pricl,et al.  Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors , 2018, Proceedings of the National Academy of Sciences.

[12]  Gianvito Grasso,et al.  Elucidating the role of surface chemistry on cationic phosphorus dendrimer-siRNA complexation. , 2018, Nanoscale.

[13]  Bhupinder Singh,et al.  Recent advances in galactose-engineered nanocarriers for the site-specific delivery of siRNA and anticancer drugs. , 2017, Drug discovery today.

[14]  A. Bohr,et al.  Anti-Inflammatory Effect of Anti-TNF-α SiRNA Cationic Phosphorus Dendrimer Nanocomplexes Administered Intranasally in a Murine Acute Lung Injury Model. , 2017, Biomacromolecules.

[15]  J. Queiroz,et al.  Smart micelleplexes as a new therapeutic approach for RNA delivery , 2017, Expert opinion on drug delivery.

[16]  M. Farrugia,et al.  The role of TNF-α in rheumatoid arthritis: a focus on regulatory T cells , 2016, Journal of clinical and translational research.

[17]  F. Aubin,et al.  Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview , 2016, RMD Open.

[18]  I. McInnes,et al.  Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases , 2015, Pharmacological Reviews.

[19]  V. Torchilin,et al.  Micelle-like nanoparticles as carriers for DNA and siRNA. , 2015, Molecular pharmaceutics.

[20]  K. Ulbrich,et al.  Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. , 2014, ACS nano.

[21]  Steven R Goldring,et al.  Development of macromolecular prodrug for rheumatoid arthritis. , 2012, Advanced drug delivery reviews.

[22]  S. Goldring,et al.  The bone, the joints and the Balm of Gilead. , 2011, Molecular pharmaceutics.

[23]  R. Bräuer,et al.  Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis , 2010, Arthritis research & therapy.

[24]  G. Tobón,et al.  The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. , 2010, Autoimmunity reviews.

[25]  Michael S. Goldberg,et al.  Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  C. Roques,et al.  Comparison of toxicity and transfection efficiency of amphiphilic block copolymers and polycationic polymers in striated muscles , 2009, The journal of gene medicine.

[27]  Y. Luan,et al.  Studies on the effects of amino acids on micellization of CTAB via surface tension measurements , 2005 .

[28]  T. Giordano,et al.  RNAi: gene-silencing in therapeutic intervention. , 2002, Drug discovery today.

[29]  Turrin,et al.  MALDI TOF mass spectrometry for the characterization of phosphorus-containing dendrimers. Scope and limitations , 2000, Analytical chemistry.

[30]  Nathalie Launay,et al.  A General Synthetic Strategy for Neutral Phosphorus‐Containing Dendrimers , 1994 .

[31]  A. Caminade,et al.  New Synthetic Strategies for Phosphorus-Containing Cryptands and the First Phosphorus Spherand Type Compound , 1994 .